Tonghua Dongbao's announcement on the approval of the clinical application for Degu insulin liraglutide injection
Tonghua Dongbao's announcement on the clinical approval of GLP-1 and GIP dual-target receptor agonists (THDBH120 for injection) for weight loss
Tonghua Dongbao's announcement on the company's participation in the national centralized drug procurement (insulin special continuation) to be selected
Announcement of resolutions of Tonghua Dongbao's 2023 Annual General Meeting of Shareholders
Legal Opinion of Tonghua Dongbao's 2023 Annual General Meeting of Shareholders
Tonghua Dongbao's 2023 Annual General Meeting of Shareholders Meeting Materials
Tonghua Dongbao's announcement on the resignation of the chairman and election of the new chairman, vice chairman, and the convener of the 11th Board Strategy Committee
Special report on Tonghua Dongbao's summary table of non-operating capital occupation and other related capital transactions in 2023
Tonghua Dongbao 2023 Internal Control Evaluation Report
Report on the performance of the Audit Committee of the Board of Directors of Tonghua Dongbao in 2023
Tonghua Dongbao's Notice on Convening the 2023 Annual General Meeting of Shareholders
Report of the Audit Committee of the Board of Directors of Tonghua Dongbao on the evaluation of the performance of accounting firms in 2023 and the performance of supervisory duties
Tonghua Dongbao's announcement on amending some provisions of the “Articles of Association” and “Rules of Procedure of the Board of Directors”
Tonghua Dongbao Company Articles of Association (revised in March 2024)
Tonghua Dongbao Board of Directors Rules of Procedure (Revised in March 2024)
Legal Opinion of Jilin Bingjian Law Firm on Tonghua Dongbao's 2024 First Extraordinary General Meeting of Shareholders
Tonghua Dongbao's Notice to Creditors on Cancelling Repurchase Shares and Repurchase and Cancelling Certain Restricted Shares to Reduce Registered Capital
Announcement of the resolution of Tonghua Dongbao's 2024 First Extraordinary General Meeting of Shareholders
Tonghua Dongbao announced the summary report on the completion of phase I clinical trials of gout dual-target inhibitors (THDBH151 tablets)
Tonghua Dongbao 2024 First Extraordinary General Meeting of Shareholders Meeting Information
No Data